What is Chantix?
Marketed by Pfizer, Inc., Chantix is a smoking cessation medication. First approved in 2006, Chantix can help smokers stop smoking by blocking nicotine receptors in the user’s body, thus eliminating or reducing the desire to smoke. Although there have been other smoking cessation treatments, including patches and therapy, Chantix is the first such nicotine receptor partial agonist which has been approved by the Federal Drug Administration (FDA). Unfortunately, within two years, Pfizer received information that Chantix could increase the risk of suicidal thoughts and other psychiatric issues in some users. By 2007, Pfizer decided to display warnings and precautions more predominantly on the packaging. Later in 2009, the FDA required Pfizer to add a Black Box Warning label for Chantix. Pfizer has since added warnings labels which highlight the product’s potential risks of increased serious mental health events, including changes in behavior, depressed mood, hostility, and suicidal thoughts.